AbelZeta Receives FDA IND Clearance for Phase 1b/2 Clinical Trial of C-CAR168 in Progressive Multiple Sclerosis

Phase 1approvedC-CAR168Positive

AI Analysis

Summary

AbelZeta Pharma received FDA IND clearance to initiate a Phase 1b/2 clinical trial of C-CAR168 for progressive multiple sclerosis, expanding development across chronic autoimmune diseases.

Clinical Trial Data

Phase

1b/2

Outcome Details

FDA IND clearance received

Importance:6/10

Sentiment:

0.85

FDA ClearanceINDMultiple SclerosisCell TherapyAutoimmune Disease

Related Companies

$MDCE $GBCYD

Read the original article

Published by PR Newswire Biotech on September 14, 2026 11:30 AM

Read Original